Non-insulin-dependent diabetes mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: In control group 44 type two diabetic patients took placebo one capsul daily for 12 weeks in addition to their medications and tests performed at begining and after trial. Intervention
Treatment - Drugs
In control group 44 type two diabetic patients took placebo one capsul daily for 12 weeks in addition to their medications and tests performed at begining and after trial.
In case group 44 patients with type two diabetes mellitus took atorvastatin 40 miligram daily for 12 weeks in addition to their medications and tests performed at begining and after tial
Sponsors
Arak university of medical sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: inclusion criteria: The patients with diabetes type 2 who had Hb A1C less than 9, triglyceride less than 250, low density lipoprotein ( LDL) between 70 to 160, high density lipoprotein (HDL) more than 35, total cholesterol less than 240 and are treated with oral hypoglycemic agents. exclusion criteria: Evidence of diabetes complications such as retinopathy, nephropathy and Glomerular Filtration Rate(GFR) less than 60, cardiovascular involvement such as Congestive Heart Failure(CHF), Ischemic Heart Diseases(IHD), acute Myocardial Infarction (MI) during recent 1 year, history of epileptic disorders, history of significant active gastrointestinal diseases such as active peptic ulcer disease in recent 1 year, history of active significant hematologic , hepatic and musculoskeletal diseases , patients who treated with insulin, patients who affected to acute illness, allergic history to statins, history of alcohol and opium consumption, breast feeder mothers and pregnant patients, patients who have consumed statins during recent 6 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TNF-alpha. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;HsCRP. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;FBS. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Insulin. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Leptin. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Adiponektin. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects on liver enzymes. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Side effects on muscle enzymes. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Mehdi Mahmudpour
Arak university of medical sciences
Outcome results
None listed